SAVA Cassava Sciences
- 22.340
- +0.610+2.81%
- 22.500
- +0.160+0.72%
Cassava Sciences News
Redemption Date Announced for Warrants
Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA)
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of JPMorgan Chase & Co. (NYSE:JPM) fell sharply during Friday's session following first-quarter earnings. Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billi
Cassava Alzheimer's Candidate Simufilam Clears Phase 3 Safety Review
Cassava Sciences' Alzheimer's Treatment Shows Promise: A Strong Buy Recommendation
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
The credibility of the clinical trial results for an experimental Alzheimer's drug has been called into question following a critical inspection report by the Food and Drug Administration (FDA).What H
Boeing, Oracle, Meta Platforms, Cassava Sciences, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Monday, the U.S. stock market presented a mixed performance. The Dow Jones index managed to turn higher, trading up by 0.12% to 38,769.66. However, the NASDAQ and the S&P 500 indices fell by 0.41%
Cassava Sciences Again Under Scrutiny Over Alzheimer's Drug Research
HC Wainwright & Co. Reiterates Buy on Cassava Sciences, Maintains $124 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Cassava Sciences (NASDAQ:SAVA) with a Buy and maintains $124 price target.
Cassava Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/05/2024 447.46% HC Wainwright & Co. → $124 Reiterates Buy → Buy 08/08/2023 447.46% HC Wainwright & Co.
Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced plans to present a virtual oral
Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Repare Therapeutics (RPTX)
Cassava Sciences Q4 EPS $(0.50) Beats $(0.52) Estimate
Cassava Sciences (NASDAQ:SAVA) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.52) by 3.85 percent. This is a 6.38 percent decrease over losses of $(0.4
Cassava Sciences 4Q Loss/Shr 50c >SAVA
Cassava Sciences 4Q Loss/Shr 50c >SAVA
Press Release: Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates -- $121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised I
Cassava Sciences Announces Key Development With Press Release
Why Alzheimers-Drug Developer Cassava Sciences Stock Is Trending
Cassava Sciences, Inc. (NASDAQ:SAVA) shares are trading higher Wednesday after the company reported top-line results of a two-year clinical safety study of simufilam, an investigational oral drug for
Simufilam Shows Stable Scores in Mild Alzheimer's Study
Cassava Sciences Reports Top-Line Results Of Two-Year Clinical Safety Study Of Simufilam, Investigational Oral Drug For Treatment Of Alzheimer's Disease
ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer's Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer's Patients Who Received Simufilam Non-C
No Decline in Cognition Scores in Patients With Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer's Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer's Patients Who Received Simufilam Non-C
Analysis
Price Target
No Data
